MAGEL2 | Cellular macromolecule biosynthetic process | GO:0034645 | 2.83E−07 |
 | Macromolecule biosynthetic process | GO:0009059 | 7.87E−07 |
 | Organic substance biosynthetic process | GO:1901576 | 3.08E−06 |
 | Biosynthetic process | GO:0009058 | 4.21E−06 |
 | Cellular biosynthetic process | GO:0044249 | 9.83E−06 |
 | Regulation of RNA metabolic process | GO:0051252 | 5.03E−05 |
 | Nucleobase-containing compound metabolic process | GO:0006139 | 6.72E−05 |
 | Nucleic acid metabolic process | GO:0090304 | 8.69E−05 |
SNORD116 | Cellular metabolic process | GO:0044237 | 8.54E−09 |
Nervous system development | GO:0007399 | 9.56E−09 | |
Metabolic process | GO:0008152 | 6.57E−08 | |
Primary metabolic process | GO:0044238 | 3.31E−07 | |
Nitrogen compound metabolic process | GO:0006807 | 5.41E−07 | |
Nucleic acid metabolic process | GO:0090304 | 9.97E−07 | |
Organic substance metabolic process | GO:0071704 | 1.15E−06 | |
Central nervous system development | GO:0007417 | 1.34E−06 | |
Hippo signaling pathway | KEGG:04390 | 6.29E−03 | |
Chronic myeloid leukemia | KEGG:05220 | 1.25E−02 | |
Neurotrophin signaling pathway | KEGG:04722 | 4.77E−02 |